- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
MEA
Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
Asia Pacific
Future Market Insights Global & Consulting Pvt. Ltd.
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Analgesics Market

Market Survey on Analgesics Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment

An In-depth Market Insights of Analgesics Market including Opioids, NSAIDs, Local Anesthetics, and Acetaminophen Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others

Request Sample

Analgesics Market Outlook (2023 to 2033)

The market share of analgesics is predicted to grow from US$ 87.3 Billion in 2023 to over US$ 132.0 Billion by 2033. There is an increase in the number of patients suffering from acute, chronic diseases such as heart disease, cancer, diabetes, stroke, and arthritis or infectious diseases such as gastrointestinal, respiratory, and neurological ailments. The rise of these diseases increases the demand for painkillers. This is expected to further drive the market share of analgesics and register a CAGR of 4.2% between 2023 and 2033

Analgesics sales will be adversely impacted by the growing population of older people because they are more susceptible to chronic and lifestyle-related diseases. Additionally, the US Food and Drug Administration's (USFDA) approval of a strong pipeline of effective drugs is expected to support analgesic market growth.

A large portion of the increase in the geriatric population is responsible for the increased demand for analgesics. By 2050, there are expected to be more than 2100 million people over the age of 60, making up around 21% of the global population. Additionally, key manufacturers are present in the market to manufacture and distribute analgesic drugs, and consumer expenditure on healthcare is increasing.

As the number of clinical trials to evaluate the safety and efficacy of a wide range of therapeutic drugs increases, the analgesics market will continue to grow. Furthermore, analgesics market trends are primarily driven by the increasing number of elderly people, cardiovascular diseases, cancer, and arthritis.

Additionally, the aging population faces frequent pain and aches, which increases market demand. The analgesics market forecast period will be characterized by remunerative opportunities for the expansion of the global analgesic market. This is a result of technological development in the pharmaceutical industry to manufacture advanced analgesic drugs.

Further, private and government funding for pharmaceutical manufacturing segments and Research and Development activities for advancing analgesic products have boosted the growth of the analgesics industry. Growth is driven by government and private initiatives to develop the pharmaceutical and analgesic industries.

Generally, opioids can be obtained through prescriptions globally. However, people are prone to obtaining fake prescriptions and obtaining these drugs easily, which is a global problem and a factor that constrains market growth.

Attributes

Details

Analgesics Market Value (2023)

US$ 87.3 Billion

Analgesics Market Expected Value (2033)

US$ 132.0 Billion

Analgesics Market Projected CAGR (2023 to 2033)

4.2%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Global Analgesics Market Historical Analysis (2017 to 2022) Vs. Forecast Outlook (2023 to 2033)

The global analgesics market expanded at 5.6% CAGR over the past 5 years. Analgesics is defined as a term that encompasses a class of drugs designed to provide pain relief without causing a loss of consciousness. Opioid analgesics have been adopted worldwide and are recognized as the most effective and widely used drugs for the treatment of severe pain.

The global demand for analgesics arises from the goal of improving healthcare outcomes. This includes pain management, which requires a multidisciplinary approach to administer. Apart from this, the formulation of opioid analgesics with abuse-deterrent properties by manufacturers has created a high demand for analgesics over the globe.

  • According to the WHO, there are only about 14% of people over the globe receive palliative care. Additionally, each year, the global estimation of people in need of palliative care is about 40 million. The low and middle-income economies carry over 78% of that population metric.

The global rise in the prevalence of neuropathic and chronic pain, as well as advancements in pain management measures, are key factors pushing global analgesics sales. The market is expected to expand at a CAGR of close to 4.2% over the forthcoming decade.

  • Short Term (2022 to 2025): There is an expectation that the pandemic will increase demand for analgesics on the global market. The pandemic has stressed healthcare systems around the world and heightened the need for advanced hospitals. A rise in the spread of infection increased the demand for analgesic drugs such as paracetamol and drove the market to grow.
  • Medium Term (2025 to 2028): The presence of effective treatment options, large-scale investment in medical research and development, and the rising adoption of analgesics among different age groups are also expected to drive the growth of the analgesics market.
  • Long Term (2028 to 2033): New pain reliever drugs are expected to create significant growth opportunities for market players due to the increasing demand for personalized medicine.
Historical CAGR (2016 to 2022) 5.6%
Historical Market Value US$ 82.9 Billion
Forecast CAGR 4.2%

Comparative Analysis of Adjacent Analgesics Markets

Analgesics Market:

Differentiating Aspects

Analgesics Market

CAGR (2023 to 2033)

4.2%

Market Valuation in 2023

US$ 87.3 Billion

Projected Market Value in 2033

US$ 132.0 Billion

Growth Factors

Rising prevalence of healthcare infrastructure.

Opportunities

An increasing number of strategic collaborations and Research and Development activities.

Key Trends

Several government initiatives to spread awareness and sedentary lifestyles of people.

Topical Pain Relief Market:

Differentiating Aspects

Topical Pain Relief Market

CAGR (2023 to 2033)

5.1%

Market Valuation in 2023

US$ 10.86 Billion

Projected Market Value in 2033

US$ 18.023 Billion

Growth Factors

Increasing prevalence of osteoarthritis and other bone-related conditions, such as diabetic neuropathy.

Opportunities

Online platforms for topical therapeutics are expected to offer lucrative growth prospects.

Key Trends

Growth in the topical pain relief industry is being driven by a growing demand for non-opioids.

Opioid Analgesics Market:

Differentiating Aspects

Opioid Analgesics Market

CAGR (2023 to 2033)

5.4%

Market Valuation in 2023

US$ 43.32 Billion

Projected Market Value in 2033

US$ 73.3 Billion

Growth Factors

The rising prevalence of orthopedic diseases, cancer, and chronic pain among the geriatric population.

Opportunities

Market manufacturers in the opioid drugs market are expected to commercialize opioid-tolerant drugs.

Key Trends

The opioid analgesics market is being fueled by rising healthcare costs and rising disposable income.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Major Factors Driving Analgesics Market

  • Rising Prevalence of Chronic Diseases

Analgesic medications treat and relieve persistent or severe pain caused by a variety of medical problems. Long-term diseases fuel industry growth. Cardiovascular disorders, in particular, contribute to industry growth. Over 20% of Americans suffer from chronic pain. This is according to a report provided by the National Center for Health Statistics of the US Centers for Disease Control and Prevention in 2019. A rise in the prevalence of diseases such as cancer has also increased the number of people suffering from chronic pain.

  • Increasing Investment in Healthcare Infrastructure

Healthcare expenditure, which helps to improve healthcare infrastructure, is another significant factor influencing the growth rate of the analgesics market. Further, various government organizations are striving to improve healthcare infrastructure by increasing funding, which will further affect market dynamics.

The surge in the geriatric population and government initiatives to spread awareness will result in the expansion of the analgesics market. Additionally, the increase in disposable income and the sedentary lifestyle of people will boost market growth.

Major Restrain Faced by Analgesics Market

  • The Severity of Abusive Opioids & their Misuse

Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased their overall sales in the global analgesics market. According to the International Association for the Study of Pain (IASP), around 20-30% of opioids prescribed for chronic pain are being misused. Besides this, as per the association, up to 10% of the total opioid consumers are addicted to it.

The consumption of opioids per capita is low in Asian countries. As per the Global Opioids Policy Initiative (GOPI), factors responsible for the low usage of opioids in Asia and Africa are requirements of the complete cost of payment by the patient, registration of patient receiving an opioid prescription, unavailability of some opioid formulations and physician requirement to receive permission for opioid prescriptions. These factors might restrain the analgesics market growth in the region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Opportunities for Analgesics Market

Many people find a certain dose of opioids to be ineffective in cases of severe pain. These patients need to take higher doses of drugs to subdue the pain, which eventually makes them opioid-tolerant, and in some cases, addicted. Hence, commercializing opioid-tolerant drugs is expected to be one of the main opportunities for players in the opioid drugs market. This will also help in reducing the side effects related to or caused by increased consumption of opioid drugs.

For pain management, opioids are largely used in North America and Western Europe but due to increasing usage of opioids for non-medical purposes, the governing bodies of respective countries are encouraging doctors to prescribe non-opioid analgesics, which provides an opportunity for the companies to introduce novel non-opioid drugs.

The introduction of non-opioid analgesics in markets such as Asia and Africa, where opioids, as well as non-opioid drugs with novel drug delivery systems, are not widely available for pain management, creates opportunities for the growth of the analgesics market.

The rising cases of opioid dependency and the abuse of painkillers have led to the development of different abuse-deterrent technologies. Expansion of manufacturing facilities across regions with scarce novel drug delivery systems will create an opportunity for sales growth in the analgesics market over the forecast period.

Major Challenges Faced by Analgesics Market

  • The Use of Biologics is on the Rise

Biotechnology is limiting the growth of the analgesics market due to the growth of biologics for treating inflammatory and neuropathic pain. Biologicals are medications that are made from living organisms, including humans, animals, and microorganisms.

These medications contain proteins, modified human hormones, or cells that produce compounds that suppress or stimulate immune system components. Biologics are more effective than analgesics, which only provide effective pain relief for 50% of patients, and are therefore used more often today.

Analgesics market growth will be hindered by the high cost of drug development and distribution. Furthermore, the lack of healthcare infrastructure and lack of skilled professionals will pose challenges. Furthermore, government regulations and a lack of awareness will further impede the market’s growth rate.

Analgesics Market Category-Wise Insights

Which Analgesics Drug Class is Witnessing Maximum Demand?

By drug type, the demand for opioids is projected to increase at a CAGR of 4.8% during the forecast period. The high demand for this drug class is because of the rising burden of chronic pain and inflammation globally.

By Indication, Which Segment is leading the Analgesics Market?

Surgical pain holds a revenue share of 53.3% in 2023 and is projected to continue accounting for over half of sales in the market by 2033. This trend in market revenue share is associated with the increasing adoption of surgical procedures worldwide.

Which is the Preferred Distribution Channel for Analgesics Sales?

Based on distribution channels, hospital pharmacies led the analgesics market with more than 30.1% market share with a CAGR of 5.4% in 2023. The controlled sales of opioid analgesics contribute to a higher market share for hospital pharmacies.

Segment Top Drug Class
Attributes Opioids
Historical CAGR 5.7%
Forecasted CAGR 4.8%
Segment Top Distribution Channel
Attributes Hospital Pharmacies
Historical CAGR 6.6%
Forecasted CAGR 5.4%

Regions Leading in Analgesics Market: Country-Wise Analysis

Regions North America
Countries United States of America
Historical CAGR 5.1%
CAGR 3.5%
Market Value (2022) US$ 14.6 Billion
Market Value (2033) US$ 50.6 Billion
Regions Europe
Countries United Kingdom
Historical CAGR 5.4%
CAGR 4.2%
Market Value (2022) US$ 1.9 Billion
Market Value (2033) US$ 5.5 Billion
Regions Asia Pacific
Countries China, Japan, India
Historical CAGR 7.1%, 5%, 7.3%
CAGR 5.7%, 4%, 6.4%
Market Value (2022) US$ 4.7 Billion, US$ 1.7 Billion, US$ 1.3 Billion
Market Value (2033) US$ 11.2 Billion, US$ 5.2 Billion, US$ 2.7 Billion

What Makes the USA Analgesics Market Dominant in North America?

The USA dominates the North American analgesics market with a total share of 86.5% in 2022 and is projected to continue exhibiting high demand through the course of the forecast period.

As per the documentation in 2016 by the National Health Institute, over 20% of adults in the USA suffer from chronic pain and 8% had high-impact chronic pain. This factor has leveraged analgesics demand in the country.

The Canadian Pain Task Force (CPTF) by the government of Canada was established in 2019 to deliver advice to guide the federal government towards better-quality methods for the prevention and management of chronic pain, a diagnosis affecting nearly 8 million people living in Canada. These initiatives will continue favoring the expansion of the analgesics market in North America.

Why is Germany’s Analgesics Market Considered Lucrative within Europe?

Germany dominates the Europe analgesics market, with a share of 23.2%. Germany’s dominance is supported by the rising number of over-the-counter (OTC) pharmacies in the country.

The trend of self-medication in Germany is highly prevalent. Sales of non-prescription analgesics via OTC pharmacies in Germany have been characterized as one of the main drivers of sales of analgesics in the country.

What Makes China Analgesics Market Highly Attractive?

China holds a 54.3% share of the East Asia market and is projected to expand at a CAGR of over 5.7%. According to research published in the Journal of Pharmaceutical Policy and Practice, the evaluation of analgesic utilization in public hospitals in China presented a rapid increase in the utilization of analgesics in China.

The utilization of NSAIDs and opioids showed a higher trend than other types of analgesics. The introduction of non-opioid analgesics in the country is expected to promote the sales of analgesics in China over the forecast period.

What is the Japan Analgesics Market Outlook?

Japan accounted for 31.8% of the East Asia analgesics market and is projected to expand at a CAGR of 4% from 2023 to 2033. There has been a swift trend favoring the demand aspect of analgesic utilization. Japan registered high sales of analgesics in 2018 and the demand was mostly concentrated in the older or geriatric population aiming to achieve a better quality of life.

Start-up Ecosystem: The Analgesics Market

Various acquisition strategies and product launches have been employed by new market players to increase their market presence.

  • According to Novartis AG, it completed its acquisition of The Medical Company on January 06, 2020. With this acquisition, Novartis AG gained new opportunities for treating disability and preventing death through vaccines.
  • Advil Dual Action was launched by GlaxoSmithKline PLC on September 10, 2020, and consists of two or more pain-relieving ingredients such as ibuprofen and acetaminophen. It helps to cure pain in two ways: Ibuprofen works through the body to target the source of pain, while acetaminophen blocks pain signals from reaching the brain.

Competitive Landscape

Some of the prominent players in the analgesics market are as follows:

  • Pfizer Inc.
  • Sun Pharmaceutical Industries, Inc.
  • Sanofi SA
  • AbbVie Inc. (Allergan plc)
  • Teva Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Endo Pharmaceuticals Inc.
  • Purdue Pharmaceuticals L.P.
  • Assertio Therapeutics, Inc.
  • Mallinckrodt Pharmaceuticals
  • Bayer AG
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Others

Recent Development: Large Scale Investment in Research and development activities for the Development of New Therapeutics

Key players are focusing on novel and innovative approaches for the development of non-opioid or non-addictive formulations for pain management. The strategy of expansion, new product launches, and approvals, by key manufacturers, is further strengthening their market presence.

  • ZYNRELEF was launched in July 2021 by Heron Therapeutics Inc. Designed to provide postsurgical analgesia for up to 72 hours after a bunionectomy, inguinal herniorrhaphy, or total knee replacement, it is an extended-release product for soft tissue or periarticular application.
  • In October 2017, Pfizer Inc., and other Leading healthcare organizations AmerisourceBergen, Blue Cross Blue Shield Association, and Prime Therapeutics are joining Walgreens (the nation's largest drugstore chains) to combat the national opioid abuse crisis by expanding the availability of safe medication disposal kiosks to an additional 900 Walgreens stores.
  • In August 2018, Sun Pharma launched Volini Maxx, a pain relief spray.

Besides these, mergers and acquisitions have emerged as key growth strategies adopted by market players. Leading companies are strengthening their product portfolio and global footprint through acquisitions.

For instance:

  • In May 2020, Assertio Therapeutics, Inc. merged with Zyla Life Sciences. The merger created a growing commercial pharmaceutical company with neurology, inflammation, and pain products.

Scope of Report

Attribute

Details

Forecast Period

2023 to 2033

Historical Data Available for

2017 to 2022

Market Analysis

US$ Million for Value and MT for Volume

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • The Middle East and Africa
  • East Asia

Key Countries Covered

USA, Canada, Brazil, Mexico, Chile, Peru, Germany, UK, Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, South Africa, and Turkey

Key Segments Covered

  • Drug Class
  • Indication
  • Route of Administration
  • Distribution Channel
  • Region

Key Companies Profiled

  • Pfizer Inc.
  • Sun Pharmaceutical Industries, Inc.
  • Sanofi SA
  • AbbVie Inc. (Allergan plc)
  • Teva Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Endo Pharmaceuticals Inc.
  • Purdue Pharmaceuticals L.P.
  • Assertio Therapeutics, Inc.
  • Mallinckrodt Pharmaceuticals
  • Bayer AG
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Others

Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Analgesics Market Segmentation by Category

By Drug Class:

  • Opioids
  • NSAIDs
  • Local Anesthetics
  • Acetaminophen

By Indication:

  • Surgical Pain
  • Cancer Pain
  • Neuropathic Pain

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • The Middle East and Africa
  • East Asia

Frequently Asked Questions

The market size of the analgesics market in 2023 is US$ 87.3 Billion.

North America is a lucrative analgesics market and is expected to dominate throughout the forecast period.

The global market of analgesics is projected to reach a valuation of US$ 132.0 Billion by 2033.

The global market of analgesics is projected to grow at approximately a CAGR of 4.2%.

Table of Content

1. Executive Summary | Analgesics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Opioids

        5.3.2. NSAIDS

        5.3.3. Local Anaesthetics

        5.3.4. Acetaminophen

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Pain Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Pain Type, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Pain Type, 2023 to 2033

        6.3.1. Surgical Pain

        6.3.2. Cancer Pain

        6.3.3. Neuropathic Pain

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Pain Type, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By Pain Type, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        7.3.1. Oral

        7.3.2. Parenteral

        7.3.3. Transdermal

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2022

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Drug Store

        8.3.4. Clinics

        8.3.5. Others

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. Asia-Pacific excluding Japan (APEJ)

        9.3.6. Japan

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. United States of America

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Pain Type

        10.2.4. By Route of Administration

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Pain Type

        10.3.4. By Route of Administration

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Pain Type

        11.2.4. By Route of Administration

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Pain Type

        11.3.4. By Route of Administration

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Western Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2.United Kingdom

            12.2.1.3. Italy

            12.2.1.4. Spain

            12.2.1.5. France

            12.2.1.6. Benelux

            12.2.1.7. Nordic

            12.2.1.8. Rest of Western Europe

        12.2.2. By Drug Class

        12.2.3. By Pain Type

        12.2.4. By Route of Administration

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Pain Type

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Rest of Eastern Europe

            13.2.1.3. Russia

        13.2.2. By Drug Class

        13.2.3. By Pain Type

        13.2.4. By Route of Administration

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Pain Type

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. APEJ Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Japan

            14.2.1.2. Australia & New Zealand

            14.2.1.3. China

            14.2.1.4. India

            14.2.1.5. Rest of APEJ

        14.2.2. By Drug Class

        14.2.3. By Pain Type

        14.2.4. By Route of Administration

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Pain Type

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

        15.2.2. By Drug Class

        15.2.3. By Pain Type

        15.2.4. By Route of Administration

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Pain Type

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Rest of MEA

        16.2.2. By Drug Class

        16.2.3. By Pain Type

        16.2.4. By Route of Administration

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Class

        16.3.3. By Pain Type

        16.3.4. By Route of Administration

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. United States of America

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Class

            17.1.2.2. By Pain Type

            17.1.2.3. By Route of Administration

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Class

            17.2.2.2. By Pain Type

            17.2.2.3. By Route of Administration

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Class

            17.3.2.2. By Pain Type

            17.3.2.3. By Route of Administration

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Class

            17.4.2.2. By Pain Type

            17.4.2.3. By Route of Administration

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Class

            17.5.2.2. By Pain Type

            17.5.2.3. By Route of Administration

            17.5.2.4. By Distribution Channel

    17.6. United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Class

            17.6.2.2. By Pain Type

            17.6.2.3. By Route of Administration

            17.6.2.4. By Distribution Channel

    17.7. Italy

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Class

            17.7.2.2. By Pain Type

            17.7.2.3. By Route of Administration

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Class

            17.8.2.2. By Pain Type

            17.8.2.3. By Route of Administration

            17.8.2.4. By Distribution Channel

    17.9. France

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Class

            17.9.2.2. By Pain Type

            17.9.2.3. By Route of Administration

            17.9.2.4. By Distribution Channel

    17.10. Benelux

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Class

            17.10.2.2. By Pain Type

            17.10.2.3. By Route of Administration

            17.10.2.4. By Distribution Channel

    17.11. Nordic

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Class

            17.11.2.2. By Pain Type

            17.11.2.3. By Route of Administration

            17.11.2.4. By Distribution Channel

    17.12. Poland

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Class

            17.12.2.2. By Pain Type

            17.12.2.3. By Route of Administration

            17.12.2.4. By Distribution Channel

    17.13. Russia

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Class

            17.13.2.2. By Pain Type

            17.13.2.3. By Route of Administration

            17.13.2.4. By Distribution Channel

    17.14. Japan

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Class

            17.14.2.2. By Pain Type

            17.14.2.3. By Route of Administration

            17.14.2.4. By Distribution Channel

    17.15. Australia & New Zealand

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Class

            17.15.2.2. By Pain Type

            17.15.2.3. By Route of Administration

            17.15.2.4. By Distribution Channel

    17.16. China

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Class

            17.16.2.2. By Pain Type

            17.16.2.3. By Route of Administration

            17.16.2.4. By Distribution Channel

    17.17. India

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Class

            17.17.2.2. By Pain Type

            17.17.2.3. By Route of Administration

            17.17.2.4. By Distribution Channel

    17.18. Japan

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Class

            17.18.2.2. By Pain Type

            17.18.2.3. By Route of Administration

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Class

            17.19.2.2. By Pain Type

            17.19.2.3. By Route of Administration

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Class

            17.20.2.2. By Pain Type

            17.20.2.3. By Route of Administration

            17.20.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Class

        18.3.3. By Pain Type

        18.3.4. By Route of Administration

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Pfizer Inc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Sun Pharmaceutical Industries, Inc.

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Sanofi SA

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. AbbVie Inc.

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Teva Pharmaceuticals

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Boehringer Ingelheim International GmbH

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Janssen Pharmaceuticals, Inc.

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Endo Pharmaceuticals Inc.

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Purdue Pharmaceuticals L.P.

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Assertio Therapeutics, Inc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Mallinckrodt Pharmaceuticals

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Bayer AG

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

        19.1.13. GlaxoSmithKline plc.

            19.1.13.1. Overview

            19.1.13.2. Product Portfolio

            19.1.13.3. Profitability by Market Segments

            19.1.13.4. Sales Footprint

            19.1.13.5. Strategy Overview

                19.1.13.5.1. Marketing Strategy

        19.1.14. Bausch Health Companies Inc.

            19.1.14.1. Overview

            19.1.14.2. Product Portfolio

            19.1.14.3. Profitability by Market Segments

            19.1.14.4. Sales Footprint

            19.1.14.5. Strategy Overview

                19.1.14.5.1. Marketing Strategy

        19.1.15. Novartis AG

            19.1.15.1. Overview

            19.1.15.2. Product Portfolio

            19.1.15.3. Profitability by Market Segments

            19.1.15.4. Sales Footprint

            19.1.15.5. Strategy Overview

                19.1.15.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 9: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 13: Latin America Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 14: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 17: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 18: Western Europe Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 19: Western Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 20: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 21: Eastern Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 22: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 23: Eastern Europe Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 24: Eastern Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 25: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 26: APEJ Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 27: APEJ Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 28: APEJ Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 29: APEJ Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 30: APEJ Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 31: Japan Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 32: Japan Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 33: Japan Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 34: Japan Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 35: Japan Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033

Table 36: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2017 to 2033

Table 38: MEA Market Value (US$ Million) Forecast by Pain Type, 2017 to 2033

Table 39: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033

Table 40: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 12: Global Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 15: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 22: Global Market Attractiveness by Pain Type, 2023 to 2033

Figure 23: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 25: Global Market Attractiveness by Region, 2023 to 2033

Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 27: North America Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 28: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 37: North America Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 40: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 47: North America Market Attractiveness by Pain Type, 2023 to 2033

Figure 48: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 50: North America Market Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 52: Latin America Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 53: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 62: Latin America Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 65: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 72: Latin America Market Attractiveness by Pain Type, 2023 to 2033

Figure 73: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 76: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: Western Europe Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 78: Western Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 79: Western Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 80: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 81: Western Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 82: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 85: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 86: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 87: Western Europe Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 88: Western Europe Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 89: Western Europe Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 90: Western Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 93: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 94: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 95: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 96: Western Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 97: Western Europe Market Attractiveness by Pain Type, 2023 to 2033

Figure 98: Western Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: Western Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: Eastern Europe Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 103: Eastern Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 104: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 105: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 106: Eastern Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 110: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 111: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 112: Eastern Europe Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 113: Eastern Europe Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 114: Eastern Europe Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 115: Eastern Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 116: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 117: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 118: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 119: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 120: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 121: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 122: Eastern Europe Market Attractiveness by Pain Type, 2023 to 2033

Figure 123: Eastern Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 124: Eastern Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 125: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 126: APEJ Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 127: APEJ Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 128: APEJ Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 129: APEJ Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 130: APEJ Market Value (US$ Million) by Country, 2023 to 2033

Figure 131: APEJ Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 132: APEJ Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: APEJ Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: APEJ Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 135: APEJ Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 136: APEJ Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 137: APEJ Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 138: APEJ Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 139: APEJ Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 140: APEJ Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 141: APEJ Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 142: APEJ Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 143: APEJ Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 144: APEJ Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 145: APEJ Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 146: APEJ Market Attractiveness by Drug Class, 2023 to 2033

Figure 147: APEJ Market Attractiveness by Pain Type, 2023 to 2033

Figure 148: APEJ Market Attractiveness by Route of Administration, 2023 to 2033

Figure 149: APEJ Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 150: APEJ Market Attractiveness by Country, 2023 to 2033

Figure 151: Japan Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 152: Japan Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 153: Japan Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 154: Japan Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 155: Japan Market Value (US$ Million) by Country, 2023 to 2033

Figure 156: Japan Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 157: Japan Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 158: Japan Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 159: Japan Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 160: Japan Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 161: Japan Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 162: Japan Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 163: Japan Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 164: Japan Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 165: Japan Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 166: Japan Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 167: Japan Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 168: Japan Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 169: Japan Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 170: Japan Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 171: Japan Market Attractiveness by Drug Class, 2023 to 2033

Figure 172: Japan Market Attractiveness by Pain Type, 2023 to 2033

Figure 173: Japan Market Attractiveness by Route of Administration, 2023 to 2033

Figure 174: Japan Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 175: Japan Market Attractiveness by Country, 2023 to 2033

Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 177: MEA Market Value (US$ Million) by Pain Type, 2023 to 2033

Figure 178: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 179: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2017 to 2033

Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 187: MEA Market Value (US$ Million) Analysis by Pain Type, 2017 to 2033

Figure 188: MEA Market Value Share (%) and BPS Analysis by Pain Type, 2023 to 2033

Figure 189: MEA Market Y-o-Y Growth (%) Projections by Pain Type, 2023 to 2033

Figure 190: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033

Figure 191: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 192: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 193: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033

Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 197: MEA Market Attractiveness by Pain Type, 2023 to 2033

Figure 198: MEA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 200: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Patient-Controlled Analgesia Pumps Market

Published : September 2023

Healthcare

Opioid Analgesics Market

Published : August 2023

Explore Healthcare Insights

View Reports

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Cookie Policy